CelLBxHealth PLC - Parsortix CTCs used for Brain Cancer detection

CelLBxHealth plc
("CelLBxHealth" or "the Company")
Parsortix CTCs used for
· Independent peer-reviewed study supports Parsortix® use in GBM
· CTC-enriched GBM samples reflect matched tumour genomics
· Findings suggest potential in GBM diagnosis and monitoring
· Study aligned with CelLBxHealth own research data on GBM patient samples
Key study findings
Researchers at Fondazione Pisana per la Scienza and Ospedali Riuniti di Livorno USL Toscana Nord Ovest,
· First proposed numerical CTC threshold for GBM, where >4 CTCs per 5 mL of blood helped distinguish patients with primary GBM from healthy controls, with 80% sensitivity and 77.3% specificity
· Parsortix-enriched CTCs contained tumour-related mutations and chromosomal changes also seen in matched tumour tissue, indicating that the captured cells reflected the patient's tumour biology
· Single-cell analysis showed that GBM CTCs were highly variable, reflecting known disease complexity
· Radionecrosis and lymphoma samples yielded no detectable CTCs, supporting the use of CTC enumeration in differentiating tumour recurrence from treatment-related change
Although GBM rarely spreads outside the brain, this study adds to growing evidence that tumour-derived cells can be detected in the blood, opening the potential for minimally invasive molecular insight into GBM biology.
In-house GBM research study
At the annual Society for Neuro-Oncology meeting, held on 19-23 November in
The peer-reviewed manuscript is available online: Lessi F. et al. (2026). Beyond the Brain: Circulating Tumor Cells as a Tool for Diagnosis and Monitoring. JCO Precision Oncology.
For further information:
|
CelLBxHealth plc |
investor@cellbxhealth.com via Walbrook PR |
|
|
|
|
Cavendish (NOMAD and Broker) |
+44 (0) 20 7220 0500 |
|
|
|
|
Walbrook PR (Investor and Media Relations) |
Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
Notes for editors
About CelLBxHealth plc
CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development, and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling, and full genomic workflows.
Commercial focus spans three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant
For more information, visit https://cellbxhealth.com/.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE